ATTORNEY DOCKET NO. 50562/P001US

PATENT U.S. Ser. No. 10/535,351

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Samuel R. Denmeade, et al.

Serial No.:

10/535,351

Filed:

April 14, 2006

Title:

ACTIVATION OF PEPTIDE PRODRUGS BY HK2

Confirmation No:

7060

Art Unit:

1654

Examiner:

Maury A. Audet

MAIL STOP: AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TERMINAL DISCLAIMER SUBMISSION

Dear Sir:

In response to a pending provisional double patenting rejection over co-pending application 11/725,135, Applicants submit a terminal disclaimer executed by the Assignee of the present application. Applicants also submit Assignee statements under 37 CFR 3.73(b) showing common ownership of the present application and co-pending application 11/725,135.

Applicants submit the required statutory disclaimer fee in the small entity amount of \$70 set forth in 37 CFR 1.20(d). If any other fees are due and are not included, the Director is authorized to charge any fees or credit any overpayment due to Deposit Account No. 23-2426 of Winstead PC (referencing matter 50562-P001US).

If there are any questions concerning this paper or the present application in general, the undersigned may be contacted at 713-650-2663.

Respectfully submitted,

WINSTEAD PC

Agent for Applicants

Date: May 19, 2010

By: Thomas P. Thrash, Reg. No. 64,805

Mail correspondence to:

WINSTEAD P.C. P. O. Box 50784 Dallas, Texas 75201 Tel: 713.650.2764

Fax: 214.745.5390